Overview and Scope
Oral cancer treatment refers to the medical interventions and therapies aimed at diagnosing, managing, and curing cancer that develops in the oral cavity or oral tissues. The specific treatment approach depends on factors such as the type, stage, and location of the cancer, as well as the patient's overall health.
Sizing and Forecast
The oral cancer treatment market size has grown strongly in recent years. It will grow from $1.9 billion in 2023 to $2.04 billion in 2024 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to interdisciplinary treatment approaches, screening programs implementation, improvements in palliative care, reconstructive surgery innovations, clinical trial discoveries..
The oral cancer treatment market size is expected to see strong growth in the next few years. It will grow to $2.66 billion in 2028 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to regulatory support for innovative therapies, advancements in biomarker research, expanding therapeutic options, improved screening and early detection, telemedicine and remote monitoring.. Major trends in the forecast period include global epidemiological changes, regulatory changes and approvals, rising awareness and early detection campaigns, patient-centric care, adjuvant therapies..
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/oral-cancer-treatment-global-market-report
Segmentation & Regional Insights
The oral cancer treatment market covered in this report is segmented -
1) By Type: Oral Squamous Cell Carcinoma, Oral Verrucous Carcinoma, Mucoepidermoid Carcinoma, Oral Cavity Lymphomas
2) By Therapy Type: Chemotherapy, Radiation Therapy, Biological Therapy
3) By Route of Administration: Oral, Injectable, Other Routes Of Administration
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
North America was the largest region in the oral cancer treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral cancer treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=13254&type=smp
Major Driver Impacting Market Growth
The growing consumption of tobacco is expected to propel the growth of the oral cancer treatment market going forward. Tobacco refers to the leaves of Nicotiana tabacum and other plants in the Nicotiana genus. Tobacco products contain poisonous substances, carcinogens, and nicotine, linked to an increased risk for specific cancers, including oral cancer. For instance, in July 2023, according to a report published by The World Health Organization, a Switzerland-based intergovernmental organization, more than 8 million people are killed by tobacco each year, including 1.3 million non-smokers who inhale second-hand smoke. Further, according to Statistics Canada, a Canada-based government agency, cigarette production increased by 5.8% compared to June 2021. Additionally, the total number of cigarettes sold rose 1.3% from May 2022, reaching 1.4 billion in June 2022. Therefore, the growing tobacco consumption is driving the growth of the oral cancer treatment market.
Key Industry Players
Major companies operating in the oral cancer treatment market report are Pfizer Inc., F. Hoffmann La Roche Ltd., Merck & Co., AbbVie Inc., Novartis AGÂ , Bayer AG, Sanofi-Aventis LLCÂ , Bristol Myers Squibb, AstraZeneca PLC, GlaxoSmithKline PLC, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG., Viatris Inc., Teva Pharmaceuticals Industries Ltd., MD Anderson Cancer Center, Bausch Health Companies Inc., Memorial Sloan Kettering Cancer Center, Aurobindo Pharma Limited, Cipla Inc., Sun Pharmaceutical Industries Ltd., Lupin Limited, Fred Hutchinson Cancer Research Center, Fresenius Kabi AG, Innovent Biologics Inc., Genentech Inc., Intas Pharmaceuticals Ltd., Ascendis Pharma A/S, Qilu Pharmaceutical Co. Ltd.
The oral cancer treatment market report table of contents includes:
1. Executive Summary
2. Oral Cancer Treatment Market Characteristics
3. Oral Cancer Treatment Market Trends And Strategies
4. Oral Cancer Treatment Market - Macro Economic Scenario
5. Global Oral Cancer Treatment Market Size and Growth
.
.
.
31. Oral Cancer Treatment Market Other Major And Innovative Companies
32. Global Oral Cancer Treatment Market Competitive Benchmarking
33. Global Oral Cancer Treatment Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Oral Cancer Treatment Market
35. Oral Cancer Treatment Market Future Outlook and Potential Analysis
36.Appendix
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
"what is oral cancer, oral cancer treatment, oral cancer diagnosis, oral cancer kya hei, kaise pehchane muh ka cancer, oral cancer treatment in gurgaon, oral cancer treatment in haryana, Mouth Cancer Treatment
Best Doctors for Oral Cancer-Surgical Treatment in India.
Oral cancer can happen in any piece of the mouth.
Most oral cancers start in the cells that cover the surfaces of your mouth, tongue, and lips.
Anybody can get oral malignancy, yet the risk is higher in the event that you are a male, use tobacco, drink lots of liquor, have HPV, or have a family background of head or neck malignancy.
Frequent sun exposure is an additional risk factor for lip cancer.
